Current advances and challenges of mesenchymal stem cells-based drug delivery system and their improvements
- PMID: 33737099
- DOI: 10.1016/j.ijpharm.2021.120477
Current advances and challenges of mesenchymal stem cells-based drug delivery system and their improvements
Abstract
Mesenchymal stem cells (MSCs) have recently emerged as a promising living carrier for targeted drug delivery. A wealth of literature has shown evidence for great advances in MSCs-based drug delivery system (MSCs-DDS) in the treatment of various diseases. Nevertheless, as this field of study rapidly advances, several challenges associated with this delivery strategy have arisen, mainly due to the inherent limitations of MSCs. To this end, several novel technologies are being developed in parallel to improve the efficiency or safety of this system. In this review, we introduce recent advances and summarize the present challenges of MSCs-DDS. We also highlight some potential technologies to improve MSCs-DDS, including nanotechnology, genome engineering technology, and biomimetic technology. Finally, prospects for application of artificially improved MSCs-DDS are addressed. The technologies summarized in this review provide a general guideline for the improvement of MSCs-DDS.
Keywords: Biomimetic technology; Drug delivery system; Genome engineering technology; Mesenchymal stem cell; Nanotechnology.
Copyright © 2021 Elsevier B.V. All rights reserved.
Similar articles
-
Enhanced Drug Delivery System Using Mesenchymal Stem Cells and Membrane-Coated Nanoparticles.Molecules. 2023 Feb 24;28(5):2130. doi: 10.3390/molecules28052130. Molecules. 2023. PMID: 36903399 Free PMC article.
-
Mesenchymal stem cells: A living carrier for active tumor-targeted delivery.Adv Drug Deliv Rev. 2022 Jun;185:114300. doi: 10.1016/j.addr.2022.114300. Epub 2022 Apr 18. Adv Drug Deliv Rev. 2022. PMID: 35447165 Review.
-
Mesenchymal stem cell-based drug delivery strategy: from cells to biomimetic.J Control Release. 2019 Jan 28;294:102-113. doi: 10.1016/j.jconrel.2018.12.019. Epub 2018 Dec 13. J Control Release. 2019. PMID: 30553849 Review.
-
Nanotechnology and bioengineering approaches to improve the potency of mesenchymal stem cell as an off-the-shelf versatile tumor delivery vehicle.Med Res Rev. 2024 Jul;44(4):1596-1661. doi: 10.1002/med.22023. Epub 2024 Feb 1. Med Res Rev. 2024. PMID: 38299924 Review.
-
Biomimetic drug delivery platforms based on mesenchymal stem cells impregnated with light-responsive submicron sized carriers.Biomater Sci. 2020 Feb 21;8(4):1137-1147. doi: 10.1039/c9bm00926d. Epub 2019 Oct 4. Biomater Sci. 2020. PMID: 31584052
Cited by
-
Stem Cell Mimicking Nanoencapsulation for Targeting Arthritis.Int J Nanomedicine. 2021 Dec 31;16:8485-8507. doi: 10.2147/IJN.S334298. eCollection 2021. Int J Nanomedicine. 2021. PMID: 35002240 Free PMC article. Review.
-
Mesenchymal Stromal Cell-Derived Extracellular Vesicles as Biological Carriers for Drug Delivery in Cancer Therapy.Front Bioeng Biotechnol. 2022 Apr 14;10:882545. doi: 10.3389/fbioe.2022.882545. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 35497332 Free PMC article. Review.
-
Targeting Myd88 using peptide-loaded mesenchymal stem cell membrane-derived synthetic vesicles to treat systemic inflammation.J Nanobiotechnology. 2022 Oct 15;20(1):451. doi: 10.1186/s12951-022-01660-x. J Nanobiotechnology. 2022. PMID: 36243859 Free PMC article.
-
Cell-derived membrane biomimetic nanocarriers for targeted therapy of pulmonary disease.Int J Pharm. 2022 May 25;620:121757. doi: 10.1016/j.ijpharm.2022.121757. Epub 2022 Apr 18. Int J Pharm. 2022. PMID: 35447225 Free PMC article. Review.
-
Advances in Mesenchymal Stem Cell-Derived Exosomes as Drug Delivery Vehicles.Front Bioeng Biotechnol. 2022 Feb 4;9:797359. doi: 10.3389/fbioe.2021.797359. eCollection 2021. Front Bioeng Biotechnol. 2022. PMID: 35186913 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
